Swedish bioprinting company CELLINK has been granted a patent from the Korean Intellectual Property Office for its Clean Chamber Technology, which enables bioprinting in a clean, sterile environment.

The patent in question protects the technology—which is used in the company’s flagship BIO X and INKREDIBLE+ bioprinters—within the Korean market. The patented technology by CELLINK is crucial to enabling desktop bioprinting while also ensuring sterility throughout the process—an important factor when producing anything related to the medical field. The patent from the Korean Intellectual Property Office helps to strengthen the company’s protection of its unique bioprinting platform and takes the company a step closer to its goal of protecting core technologies in the bioprinting field. “We are extremely excited to have another granted patent for our revolutionary technology platform,” said Erik Gatenholm , CEO of CELLINK. “As a globally recognized leader in the field, it […]

Click here to view original web page at www.3dprintingmedia.network